The pathology of male breast cancer

International Journal of Cancer Prevention

Volumn 2, Issue 3, 2005, Pages 213-223

  Chakrabarti, J ^a   Rampaul, R S ^a,b   Guevara, C ^a   Pinder, S E ^a   Ellis, I O ^a   Robretson, J F ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; TUMOR MARKER;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GENETICS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; DIFFERENTIAL DIAGNOSIS; FAMILY HISTORY; GENE MUTATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE BREAST; MASTECTOMY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SENTINEL LYMPH NODE BIOPSY;

EID: 35448998938     PISSN: 15541134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Perkins, H; Middleton, LP. Breast cancer in men. BMJ 2003; 327: 239-240
2. Iredale, R; Williams, B; Brain K. Breast Cancer in men: Group is exploring issues for men in the United Kingdom. BMJ 2003 327: 930-931.
3. Giordano, SH; Cohen, DS; Buzdar, AU. et al. Breast Carcinoma in Men: Cancer 2004; 101: 51-7
4. Giordano, SH; Buzdar, AU; Hortobagyi, GN. Breast Cancer in Men: Ann Int Med; 2002; 137: 678-687
5. Kanhai; Robert, CJ; Hage, J et al. Short term and Long Term Histologic Effects of Castration and Estrogen Treatment on Breast Tissue of 14 Male to female Transsexuals in Comparison with Two Chemically Castrated Men. The American Journal of Surgical Pathology. 2000(24)1
6. Ravandi-Kashani, F; Hayes, TG Male Breast Cancer: A Review of the Literature. European Journal of Cancer. 1998 34(9) 1341-1347
7. Lanfranco, F; Kamischke, A; Zitzmann, M; Nieschlag, E. Klinefelter's syndrome. Lancet. 2004 Jul 17; 364(9430):273-83.
8. Hultborn, R; Hanson, C; Kopf, I. Prevalence of Klinefelter's syndrome in male breast cancer patients: Anticancer Res. 1997 Nov-Dec; 17(6D): 4293-7.
9. Cocco, P; Figgs, L; Dosemeci, M et al. Case-control study of occupational exposures and male breast cancer. Occupational and Environmental Medicine. 1998(55) 599-604
10. Erlichman, C; Murphy, KC; Elhakim, T. Male breast cancer: A 13-year review of 89 patients. J Clin Oncol 1984 (2) 903-9
11. Borgen, PI; Wong, GY; Vlamis, V et al. Current management of male breast cancer: a review of 104 cases. Ann Surg 1992 (215) 451-9
12. Stalsberg, H; Thomas, DB; Rosenblatt, K.A; Jimenez, LM; McTiernan, A; Stemhagen, A; Thompson, WD; Curnen, MG; Satariano, W; Austin DF. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control. 1993 Mar; 4(2): 143-51.
13. Hittmair, AP; Lininger, RA; Tavassoli, FA. Ductal Carcinoma in the Male Breast. Cancer 1998 Nov 83(10): 2139-49
14. Tumours of the male breast (1) 110-112 in Tavassoli, FA; Devilee P. (2003) WHO Classification of Tumours. Pathology and Genetics. Tumours of the Breast and the Female Organs.
15. Sanchez, AG; Villaneuva, AG; Redondo, C. Lobular carcinoma of the breast in a patient with Kleinfelter's syndrome. A case with bilateral, synchronous, histologically different breast tumors. Cancer 1986: 57: 1181-3
16. Schiedbach, H; Dworak, O; Schmucker, B et al. Lobular carcinoma of the breast in an 85-year-old man. European Journal of Surgical Oncology 1999
17. Michaels, BM; Nunn, CR; Roses, DF Lobular Carcinoma of the male breast Surgery 115: 402-405.
18. Acs, G; Lawton, TJ; Rebbeck, TR; LiVolsi, VA; Zhang, PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115: 85-98.
19. Willsher, PC; Leach, IH; Ellis, IO; Bell, JA; Elston, CW; Bourke, JB; Blamey RW, Robertson, JFR. Male Breast Cancer: Pathological and Immunohistochemical Features. Anticancer Research 17: 2335-2338.
20. Cutuli, B; Dilhuydy, JM; de la Fontan, B; Berlie, J; Lacroze, M; Lesaunier, F; Graic, Y; Tortochaux, J; Resbaut, M; Lesimple, T; Gamelin, E; Campana F, Reme-Saumon, M; Moncho-Bernier, V; Cuilliere, JC; Marchal, C; De Gislain, G; Nguyen TD, Teissier E, Velten M (1997). Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer 33: 35-38.
21. Evans, DB; Chichlow, RW. Carcinoma of the male breast and Kleinfelters syndrome: is there an association? CA: A Cancer Journal For Clinicians 1987 37(4); 246-251
22. Antoniou, P. D. P; Pharoah, S; Narod, H. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. The American Journal of Human Genetics, volume 72 (2003), page 1117
23. Easton, DF; Steele, L; Fields, P; Ormiston, W; Averill, D et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13 Am J Hum Genet 1997; 61: 120-8.
24. Kwiatkowska, E; Teresiak, M; Filas, V; Karczewska, A; Breborowicz, D; Mackiewicz A. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res. 2003 Oct 1; 9(12): 4452-9.
25. Rampaul, RS; Pinder, SE; Gullick, WJ et al. HER-2 in breast cancer-methods of detection, clinical significance and future prospects for treatment. Critical reviews in Oncology/Haematology 43 (2002) 231-244
26. Slamon, DJ; Clark, GM; Wong, SG; Levin, WJ; Ulrich, A; McGuire, WL Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82
27. Rudlowski, C; Friedrichs, N; Faridi, A; Fuzesi, L; Moll, R; Bastert, G; Rathg Buttner R. HER-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Research and Treatment 84: 215-233, 2004
28. Rayson, D; Erlichman, C; Suman, VJ. Molecular markers in male breast carcinoma. Cancer. 1998 Nov 1; 83(9): 1947-55.
29. Blin, N; Kardas, I; Welter, C et al: Expression of the c-erbB-2 proto-oncogene in male breast carcinomas: lack of prognostic significance. Oncology 50: 408-411, 1993
30. Payne, S; Bruce, DM; Heys, SD et al: Prognostic parameters in male breast cancer. J Pathol 175s: 143, 1994 (abstr)
31. Bruce, DM; Heys, SD; Payne, S et al: Male breast cancer: Clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Cancer 22: 42-46, 1996
32. Wang-Rodriguez, J; Cross, K; Gallagher, S; Djahanban, M; Armstrong, JM; Wiedner, N; Shapiro, DH. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol. 2002 Aug; 15(8): 853-61.
33. Mourao Netto, M; Logullo, AF; Nonogaki, S; Brentani, RR; Brentani, MM. Expression of c-erbB-2, p53 and c-myc proteins in male breast carcinoma: Comparison with traditional prognostic factors and survival. Braz J Med Biol Res. 2001 Jul; 34(7): 887-94.
34. Joshi, MG; Lee, AK; Loda, M; Camus, MG; Pedersen, C; Heatley, GJ; Hughes, KS. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996 Feb l; 77(3): 490-8.
35. Pich, A; Margaria, E; Chiusa, L. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J Clin Oncol. 2000 Aug; 18(16): 2948-56
36. Hockenbery, D; Nunez, G; Milliman, C; Schreiber, RD; Korsmeyer, SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990 Nov 22; 348(6299): 334-6.
37. Alsabeh, R; Wilson, CS; Ahn, CW; Vasef, MA; Battifora, H. Expression of bcl-2 by breast cancer: a possible diagnostic application. Mod Pathol. 1996 Apr; 9(4): 439-44
38. Bargmann, CI; Hung, M-C; Weinberg, RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230
39. Bhargava, V; Thor, A; Deng, G et al: The association of p53 immunopositivity with tumour proliferation and other indicators in breast cancer. Modern Pathol 7: 361-368, 1994 (Abstract)
40. Locker, AP; Dowle, CS; Ellis, IO et al: c-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer 60: 669-672, 1989
41. Idelevich, E Mozes, M; Ben-Baruch, N; Huszar, M; Kruglikova, A; Katsnelson, R; Shani A. Oncogenes in male breast cancer. Am J Clin Oncol. 2003 Jun; 26(3): 259-61
42. Muir, D; Kanthan, R; Kanthan, SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med. 2003 Jan; 127(1): 36-41
43. Pich, A; Margaria, E; Chiusa, L. Bcl-2 expression in male breast carcinoma. Virchows Arch. 1998 Sep; 433(3): 229-35.
44. Temmim, L; Luqmani, YA; Jarallah, M; Juma, I; Mathew, M. Evaluation of prognostic factors in male breast cancer. Breast. 2001 Apr; 10(2): 166-75.
45. Sutherland, RL; Musgrove, EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004 Jan; 9(1): 95-104.
46. Barnes, DM; Gillett, CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat. 1998; 52(1-3): 1-15.
47. Barlund, M; Kuukasjarvi, T; Syrjakoski, K; Auvinen, A; Kallioniemi A. Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer. 2004 Oct 10; 111(6): 968-71.
48. Arber, N; Hibshoosh, H; Zhang, Y; Han, E; Sgambato, A; Weinstein I. Overexpression of cyclin D1 in both female and male breast cancers [Abstract]. Proc Annu Meet Am Assoc Cancer Res. 1995; 36: 1350-1350.
49. Teller, MN; Stock, CC; Stohr, G; Merker, PC; Kaufman, RJ; Escher, GC; Bowie, M. Biologic characteristics and chemotherapy of 7,12-dimethylbenz[a]anthracene-induced tumors in rats. Cancer Res. 1966 Feb; 26(2): 245-52.
50. Poulin, R; Baker, D; Labile F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat. 1988 Oct; 12(2): 213-25.
51. Allegra, JC; Lippman, ME; Thompson, EB; Simon, R; Barlock, A; Green, L; Huff, KK; Do, HM; Aitken, SC. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 1979 May; 39(5): 1447-54.
52. Langer, M; Kubista, E; Schemper, M; Spona J. Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obstet. 1990; 247(4): 203-9.
53. Miller, WR; Telford, J; Dixon, JM; Hawkins, RA. Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer Clin Oncol. 1985 Apr; 21(4): 539-42.
54. Bryan, RM; Mercer, RJ; Bennett, RC; Rennie, GC; Lie, TH; Morgan, F Androgen receptors in breast cancer. Cancer. 1984 Dec 1; 54(11): 2436-40.
55. Birrell, SN; Roder, DM; Horsfall, DJ; Bentel, JM; Tilley WD. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol. 1995 Jul; 13(7): 1572-7.
56. Kuenen-Boumeester, V; Van der Kwast, TH; Claassen, CC; Look, MP; Liem, GS; Klijn, JG; Henzen-Logmans, SC. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer. 1996 Aug; 32A(9): 1560-5.
57. Nomura, Y; Yamagata, J; Takenaka, K; Tashiro, H. Steroid hormone receptors nd clinical usefulness in human breast cancer. Cancer. 1980 Dec 15; 46(12 Suppl): 2880-3.
58. Calandra, RS; Charreau, EH; Royer de Giaroli, M; Baldi, A. Incidence of estrogen, progesterone and prolactin receptors in human breast cancer. Prog Clin Biol Res. 1984; 142: 97-108.
59. Mercer, RJ; Bryan, RM; Bennett, RC. Hormone receptors in male breast cancer. Aust N Z J Surg. 1984 Jun; 54(3): 215-8.
60. Pacheco, MM; Oshima, CF; Lopes, MP; Widman, A; Franco, EL; Brentani, MM. Steroid hormone receptors in male breast diseases. Anticancer Res. 1986 Sep-Oct; 6(5): 1013-7.
61. Sasano, H; Kimura, M; Shizawa, S; Kimura, N; Nagura, H. Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab. 1996 Aug; 81(8): 3063-7
62. Soreide, JA; Lea, OA; Varhaug, JE; Skarstein, A; Kvinnsland, S. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992 Apr; 18(2): 112-8.
63. Pich, A; Margaria, E; Chiusa, L; Candelaresi, G; Dal Canton, O. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. Br J Cancer. 1999 Feb; 79(5-6): 959-64.
64. Kidwai, N; Gong, Y; Sun, X; Deshpande, CG; Yeldandi, AV; Rao, MS; Badve S. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res. 2004; 6(1): R18-23. Epub 2003 Nov. 07
65. Munoz de Toro, MM; Maffini, MV; Kass, L; Luque, EH. Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol. 1998 Nov; 67(4): 333-9.
66. Stalsberg, H; Thomas, DB; Rosenblatt, KA; Jimenez, LM; McTiernan, A; Stemhagen, A; Thompson, WD; Curnen, MG; Satariano, W; Austin, DF. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control. 1993 Mar; 4(2): 143-51.
67. Donegan, WL; Redlich, PN; Lang, PJ; Gall, MT. Carcinoma of the breast in males: A multiinstitutional survey. Cancer. 1998 Aug 1; 83(3): 498-509.
68. Willsher, PC; Leach, IH; Ellis, IO; Bourke, JB; Blamey, RW; Robertson, JFR. A comparison outcome of male breast cancer with female breast cancer. Am J Surg. 1997 Mar; 173(3): 185-8
69. Herman, K; Lobaziewicz, W; Skotnicki, P; Fortuna, J; Kusy, T; Lesniak. Male Breast cancer. Does the prognosis differ compared to female? Neoplasma. 2000; 47(3): 191-5
70. Vetto, J; Jun, SY; Paduch, D; Eppich, H; Shih, R. Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg. 1999 May; 177(5): 379-83.
71. Rudan, I; Rudan, N; Basic, N; Basic, V; Rudan, D; Jambrisak, Z. Differences between male and female breast cancer. III. Prognostic features. Acta Med Croatica. 1997; 51(3): 135-41.
72. Goyal, A; Horgan, K; Kissin, M; Yiangou, C; Sibbering, M; Lansdown, M; Newcombe, RG; Mansel, RE; Chetty, U; Ell, P; Fallowfield, L. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol. 2004 Jun; 30(5): 480-3
73. Erlichman, C; Murphy, KC; Elhakim, T. Male breast cancer: A 13 year reviw of 89 patients. J Clinical Oncol. 1984; (2): 903-9
74. Ribeiro, G; Swindell, R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer. 1992; (65): 252-4
75. Vinod, SK; Pendlebury, SC. Carcinoma of the male breast: A review of adjuvant therapy. Australas Radiol. 1999 Feb; 43(1): 69-72
76. Bagley, CS; Wesley, MN; Young, RC; Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987 Feb; 10(1): 55-60
77. Couch, FJ; Farid, LM; DeShano, ML; Tavtigian, SV; Calzone, K; Campeau, L; Peng, Y; Bogden, B; Chen, Q; Neuhausen, S; Shattuck-Eidens, D; Godwin AK; Daly, M; Radford, DM; Sedlacek, S; Rommens, J; Simard, J; Garber, J; Merajver, S; Weber, BL. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996 May; 13(1): 123-5.
78. Friedman, LS; Gayther, SA; Kurosaki, T; Gordon, D; Noble, B; Casey, G; Ponder, BA; Anton-Culver, H. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997 Feb; 60(2): 313-9.
79. Mavraki, E; Gray, IC; Bishop, DT; Spurr, NK. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Br J Cancer. 1997; 76(11): 1428-31.
80. Haraldsson, K; Loman, N; Zhang, QX; Johannsson, O; Olsson, H; Borg, A. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res. 1998 Apr 1; 58(7): 1367-71.
81. Csokay, B; Udvarhelyi, N; Sulyok, Z; Besznyak, I; Ramus, S; Ponder, B; Olah, E. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res. 1999 Mar 1; 59(5): 995-8.
82. Sverdlov, RS; Barshack, I; Bar Sade, RB; Baruch, RG; Hirsh-Yehezkel, G; Dagan, E; Feinmesser, M; Figer, A; Friedman, E. Genetic analyses of male breast cancer in Israel. Genet Test. 2000; 4(3): 313-7.
83. Kwiatkowska, E; Teresiak, M; Lamperska, KM; Karczewska, A; Breborowicz, D; Stawicka, M; Godlewski, D; Krzyzosiak, WJ; Mackiewicz, A. BRCA2 germline mutations in male breast cancer patients in the Polish population. Hum Mutat. 2001; 17(1): 73.
84. Kwiatkowska, E; Teresiak, M; Breborowicz, D; Mackiewicz, A. Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer. Int J Cancer. 2002 Apr 20; 98(6): 943-5.
85. Wolpert, N; Warner, E; Seminsky, MF; Futreal, A; Narod, SA. Prevalence of BRCAI and BRCA2 mutations in male breast cancer patients in Canada. Clin Breast Cancer. 2000 Apr; l(1): 57-63; discussion 64-5.
86. Basham, VM; Lipscombe, JM; Ward, JM; Gayther, SA; Ponder, BA; Easton, DF; Pharoah, PD. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res. 2002; 4(1): R2. Epub 2001 Nov 21.
87. Ottini, L; Masala, G; D'Amico, C; Mancini, B; Saieva, C; Aceto, G; Gestri, D; Vezzosi, V; Falchetti, M; De Marco, M; Paglierani, M; Cama, A; Bianchi, S; Mariani-Costantini, R; Palli, D. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003 Jan 15; 63(2): 342-7.
88. Tirkkonen, M; Kainu, T; Loman, N; Johannsson, OT; Olsson, H; Barkardottir, RB; Kallioniemi, OP; Borg, A. Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chromosomes Cancer. 1999 Jan; 24(1): 56-61.
89. Andre, S; Fonseca, I; Pinto, AE et al. Male Breast Cancer - A reappraisal of clinical and biologic indicators of prognosis. Acta Oncol. 2001; 40(4): 472-8
90. Shiptz, B; Bomstein, Y; Sternberg, A et al. Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. J Surg Oncol. 2000 Dec; 75(4): 252-7
91. Clark, JL; Nguygen, PL; Jaszcz, WB, et al. Prognostic Variables in male breast cancer. Am Surg. 2000 May; 66(5): 502-11
92. Bloom, KJ; Govil, H; Gatusso, P et al. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001 Oct; 182(4): 389-92
93. Anelli, A; Anelli, TFM, Youngson, B; Rosen, PP; Borgen, PI. Mutations of the p53 gene in male breast cancer. Cancer 1995; 75: 2233-8.
94. Fox, SB; Rogers, S; Day, CA; Underwood, JC. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. Journal of Pathology 1992 Jan; 166(1): 13-8.
95. Chung, HC; Kim, DL; Koh, EH; Kim, JH; Rob, JK; Min, JS; Lee, KS; Yang, WI; Kim, BS; Lee, KB. Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. Yonsei Med J. 1991 Jun; 32(2): 126-30.
96. Takeuchi, H; Shirasaka, C; Tsuji, K; Ueo, H. Clinicopathological study of Japanese male breast carcinoma. Breast Cancer. 2003; 10(3): 249-53.
97. Williams, WL Jr; Powers, M; Wagman, LD. Cancer of the male breast: a review. J Natl Med Assoc. 1996 Jul; 88(7): 439-43.
98. Cutuli, B; Lacroze, M; Dilhuydy, JM et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995 Nov; 31A (12): 1960-4.
99. Morimoto, T; Komaki, K; Yamakawa, T; Tanaka, T; Oomine, Y; Konishi, Y; Mori, T; Monden, Y. Cancer of the male breast. J Surg Oncol. 1990 Jul; 44(3): 180-4
100. Goss, PE; Reid, C; Pintilie, M; Lim, R; Miller, N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer. 1999 Feb 1; 85(3): 629-39.
101. Tan, PH; Sng, IT. Male breast cancer: a retrospective study with immunohistochemical analysis of hormone receptor expression. Pathology. 1997 Feb; 29(1): 2-6.
102. Sasano, H; Kimura, M; Shizawa, S; Kimura, N; Nagura, H. Aromatase and steroid receptors in gynecomastia and male breast carcinoma: an immunohistochemical study. J Clin Endocrinol Metab. 1996 Aug; 81(8): 3063-7
103. Borgen, PI; Senie, RT; McKinnon, WM; Rosen, PP. Carcinoma of the malebreast: analysis of prognosis compared with matched female patients. Ann Surg Oncol. 1997 Jul-Aug; 4(5): 385-8.
104. Dawson, PJ; Schroer, KR; Wolman, SR. ras and p53 genes in male breast cancer. Mod Pathol. 1996 Apr; 9(4): 367-70.